Tuesday 1 December

09.30 – 09.40

Welcome
Chaired by Steve Bates

09:40 – 09.50

UK Strategy Update
Steve Bates OBE
Chief Executive Officer, BioIndustry Association

09.50 – 10.00

UK Manufacturing Perspective
A snapshot of the UK’s biomanufacturing landscape

Dr Stephen Ward
Chief Manufacturing Officer, Cell & Gene Therapy Catapult

10.00 – 11.00

The BIA COVID19 Vaccine Manufacturing Taskforce story

11.00 – 11.30

Networking

11.30 – 12.00

COVID19 Vaccine Manufacturing legacy 

12.00 – 12.15

Richard Wilson Impact Award
Presented by Dr Kit Erlebach, Fujifilm Diosynth Biotechnologies & Chair of BIA MAC

12.15 – 13.15

Early Career Researcher Poster flashes
20 young researchers will present their projects and outcomes ahead of the Poster Prize voting
Chaired by Kit Erlebach, Fujifilm

13.15 – 14.20

Networking

14.20 – 14.45

LeaP presentation

14.45 – 15.15

Chaired by Nick Gardiner, BIA

MMIP overview - strategy and progress update
An overview will be given of the ongoing Medicines Manufacturing Industry Partnership (MMIP) initiatives, including high level updates from each of the MMIP work streams.

Andy Evans
VP Clinical Manufacturing and Supply, AstraZeneca and Chair of MMIP

15.15 – 16.00

Peter Dunnill Award Presentation and lecture
Presented by Sharon Grimster, last year’s recipient

16.00 – 16.10

Summary and close of day one
Steve Bates OBE
Chief Executive Officer, BioIndustry Association

19.00 – 21.30

Evening Networking
Tribute to Simon Ellison

Wednesday 2 December

Parallel sessions

Keynote

09.30 – 10.45

Workshop 1: Arthritis

Chaired by Sharon Grimster

1) The development of biopharmaceuticals for Arthritis
Ursula Ney

2) Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AuToDeCRA)
Our team is developing AuToDeCRA as a means to ‘switch off’ rheumatoid arthritis, and potentially applicable to other areas of autoimmunity. We have completed phase 1 and are gearing up for phase 2, where we will compare administration routes. This presentation will also cover, briefly, the Newcastle ‘offer’ in terms of Advanced Therapies development and delivery.
Professor John Isaacs
Newcastle University Translational and Clinical Research Institute, Newcastle-upon-Tyne, UK & Associate Medical Director (Research), Newcastle upon Tyne Hospitals NHS Foundation Trust

3) Patient story
Versus Arthritis

Workshop 2: Digital Savvy Workforce

Chaired by Kate Barclay

1) Skills Overview/Launch of CATTS
Kate Barclay
Skills Consultant, BioIndustry Association

2) Learning pathways in Data Science & AI apprenticeships
Cambridge Spark are the UK's leading specialist Data Science & AI apprenticeship training provider. This talk will cover how you can develop Analytics, Data Science & AI skills and capability by using government-funded apprenticeships and degree apprenticeships, from entry-level all the way through to MSc. Cambridge Spark's cutting edge training in Data Science and AI includes Data Analyst, Data Scientist, and Machine Learning Engineer apprenticeships as well as Data Science degree apprenticeships at BSc and MSc levels.
Tony Clark
Head of Training Solutions, Cambridge Spark (20 mins)

3) Digital apprenticeships
Becca Goodwin
Digital Apprentice, AstraZeneca

10.45 – 11.15

Networking

11.15 – 13:00

bioProcessUK 4.0 technology showcase

Chair Oliver Hardick
6 x 5 min pitches from new enabling technology companies - Dragon’s Den style voting for best technology

Mass photometry – a novel method to study biomolecules
Mass photometry is a novel method recently developed by scientists at the University of Oxford to determine the mass and mass distributions of native single molecules in solution. In a label-free manner and using only a few microlitres of sample it is possible to study the mass, oligomeric state, binding behaviour and much more in a single assay that takes no more than a few minutes.
Dr James Wilkinson
Sales Director, Refeyn

FourPlus: Immersive Technologies for the Life Sciences Sector
FourPlus creates powerful, virtual and augmented reality tools for the life sciences sector. Harnessing these state-of-the-art immersive technologies, we provide innovative solutions for lab design, lab training, data visualisation and technology showcasing.   
Dr Hayley Mulhall
Founder and CEO, FourPlus

13.00 – 14.00

Networking

14.00 – 15.15

bioProcessUK 4.0

How technology innovation can potentially improve bioprocesses and achieve some of the objectives of Industry 4.0.
In order to address the challenges faced as we move forward with the adoption of Industry 4.0 we have developed several new technologies and product platforms that supplement the existing toolboxes and are potential enablers for process improvement and optimization in the design of end-to-end processes. These will be illustrated and demonstrate how it should be possible to develop process flows using the technology platforms best optimised for optimal productivity based on kg product produced per year per unit facility footprint.
Dr Peter Levison
Executive Director Business Development, Pall Biotech

Peptide-based biomaterials for 3D cell culture and bioprinting
Biogelx supply unique peptide-based biomaterials to researchers around the globe who are interested in 3D cell culture and bioprinting. The core technology of these functional materials was developed at the University of Strathclyde by Prof Rein Ulijn, and Biogelx continue to develop new products and applications around this knowledge base. The company remains in touch with its academic roots by supporting 6 ongoing PhD studentships and acting as a contributing partner in a multicenter H2020-funded project involving academic and industry groups.
Dr Chris Allen
Development Scientist, Biogelx

Title TBC
Gerald Kierans
Pfizer Grange Castle

15.15 – 15.30

Closing summary and awards
Steve Bates
Chief Executive Officer, BioIndustry Association